Aristolochic acid-associated urothelial cancer in Taiwan
Open Access
- 9 April 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 109 (21), 8241-8246
- https://doi.org/10.1073/pnas.1119920109
Abstract
Aristolochic acid, a potent human carcinogen produced by Aristolochia plants, is associated with urothelial carcinoma of the upper urinary tract (UUC). Following metabolic activation, aristolochic acid reacts with DNA to form aristolactam (AL)-DNA adducts. These lesions concentrate in the renal cortex, where they serve as a sensitive and specific biomarker of exposure, and are found also in the urothelium, where they give rise to a unique mutational signature in the TP53 tumor-suppressor gene. Using AL-DNA adducts and TP53 mutation spectra as biomarkers, we conducted a molecular epidemiologic study of UUC in Taiwan, where the incidence of UUC is the highest reported anywhere in the world and where Aristolochia herbal remedies have been used extensively for many years. Our study involves 151 UUC patients, with 25 patients with renal cell carcinomas serving as a control group. The TP53 mutational signature in patients with UUC, dominated by otherwise rare A:T to T:A transversions, is identical to that observed in UUC associated with Balkan endemic nephropathy, an environmental disease. Prominent TP53 mutational hotspots include the adenine bases of 5′AG (acceptor) splice sites located almost exclusively on the nontranscribed strand. A:T to T:A mutations also were detected at activating positions in the FGFR3 and HRAS oncogenes. AL-DNA adducts were present in the renal cortex of 83% of patients with A:T to T:A mutations in TP53, FGFR3, or HRAS. We conclude that exposure to aristolochic acid contributes significantly to the incidence of UUC in Taiwan, a finding with significant implications for global public health.Keywords
This publication has 33 references indexed in Scilit:
- Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acidKidney International, 2012
- Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adductsNucleic Acids Research, 2011
- Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adductsNucleic Acids Research, 2011
- Risks of Kidney Failure Associated With Consumption of Herbal Products Containing Mu Tong or Fangchi: A Population-Based Case-Control StudyAmerican Journal of Kidney Diseases, 2010
- Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer RiskJNCI Journal of the National Cancer Institute, 2009
- DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cellsNucleic Acids Research, 2009
- Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003Chinese Medicine, 2008
- TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumoursInternational Journal of Cancer, 2008
- Upper Urinary Tract Urothelial Carcinoma in Eastern Taiwan: High Proportion Among All Urothelial Carcinomas and Correlation with Chronic Kidney DiseaseJournal of the Formosan Medical Association, 2007
- Aristolochic acid and the etiology of endemic (Balkan) nephropathyProceedings of the National Academy of Sciences of the United States of America, 2007